Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia

J. Ruda-Kucerova, Z. Babinska, T. Stark, V. Micale,

. 2017 ; 32 (1) : 121-133. [pub] 20170418

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc18010667

Ketamine may prove to be a potential candidate in treating the widespread drug addiction/substance abuse epidemic among patients with schizophrenia. Clinical studies have shown ketamine to reduce cocaine and heroin cravings. However, the use of ketamine remains controversial as it may exacerbate the symptoms of schizophrenia. Therefore, the aim of this study is to characterize the effects of ketamine on drug addiction in schizophrenia using the methylazoxymethanol (MAM) acetate rat model on operant IV methamphetamine (METH) self-administration. MAM was administered intraperitoneally (22 mg/kg) on gestational day 17. Locomotor activity test and later IV self-administration (IVSA) were then performed in the male offspring followed by a period of forced abstinence and relapse of METH taking. After reaching stable intakes in the relapse phase, ketamine (5 mg/kg) was administered intraperitoneally 30 min prior to the self-administration session. As documented previously, the MAM rats showed a lack of habituation in the locomotor activity test but developed stable maintenance of METH self-administration with no difference in operant behaviour to control animals. Results show that ketamine treatment significantly reduced the METH intake in the control animals but not in MAM animals. Ketamine effect on METH self-administration may be explained by increased glutamatergic signalling in the prefrontal cortex caused by the N-methyl-D-aspartate antagonism and disinhibition of GABA interneurons which was shown to be impaired in the MAM rats. This mechanism may at least partly explain the clinically proven anti-craving potential of ketamine and allow development of more specific anti-craving medications with fewer risks.

000      
00000naa a2200000 a 4500
001      
bmc18010667
003      
CZ-PrNML
005      
20180418105029.0
007      
ta
008      
180404s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12640-017-9718-9 $2 doi
035    __
$a (PubMed)28421529
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ruda-Kucerova, Jana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. jkucer@med.muni.cz.
245    10
$a Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia / $c J. Ruda-Kucerova, Z. Babinska, T. Stark, V. Micale,
520    9_
$a Ketamine may prove to be a potential candidate in treating the widespread drug addiction/substance abuse epidemic among patients with schizophrenia. Clinical studies have shown ketamine to reduce cocaine and heroin cravings. However, the use of ketamine remains controversial as it may exacerbate the symptoms of schizophrenia. Therefore, the aim of this study is to characterize the effects of ketamine on drug addiction in schizophrenia using the methylazoxymethanol (MAM) acetate rat model on operant IV methamphetamine (METH) self-administration. MAM was administered intraperitoneally (22 mg/kg) on gestational day 17. Locomotor activity test and later IV self-administration (IVSA) were then performed in the male offspring followed by a period of forced abstinence and relapse of METH taking. After reaching stable intakes in the relapse phase, ketamine (5 mg/kg) was administered intraperitoneally 30 min prior to the self-administration session. As documented previously, the MAM rats showed a lack of habituation in the locomotor activity test but developed stable maintenance of METH self-administration with no difference in operant behaviour to control animals. Results show that ketamine treatment significantly reduced the METH intake in the control animals but not in MAM animals. Ketamine effect on METH self-administration may be explained by increased glutamatergic signalling in the prefrontal cortex caused by the N-methyl-D-aspartate antagonism and disinhibition of GABA interneurons which was shown to be impaired in the MAM rats. This mechanism may at least partly explain the clinically proven anti-craving potential of ketamine and allow development of more specific anti-craving medications with fewer risks.
650    _2
$a analýza rozptylu $7 D000704
650    _2
$a zvířata $7 D000818
650    _2
$a stimulanty centrálního nervového systému $x aplikace a dávkování $7 D000697
650    _2
$a operantní podmiňování $x účinky léků $7 D003216
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a ketamin $x farmakologie $x toxicita $7 D007649
650    _2
$a lokomoce $x účinky léků $7 D008124
650    _2
$a methamfetamin $x aplikace a dávkování $7 D008694
650    _2
$a methylazoxymethanolacetát $x analogy a deriváty $x toxicita $7 D008746
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a schizofrenie $x chemicky indukované $x farmakoterapie $7 D012559
650    _2
$a autoaplikace $7 D012646
655    _2
$a časopisecké články $7 D016428
700    1_
$a Babinska, Zuzana $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
700    1_
$a Stark, Tibor $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic.
700    1_
$a Micale, Vincenzo $u CEITEC - Central European Institute of Technology, Masaryk University, Brno, Czech Republic. Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, School of Medicine, University of Catania, Catania, Italy.
773    0_
$w MED00180457 $t Neurotoxicity research $x 1476-3524 $g Roč. 32, č. 1 (2017), s. 121-133
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28421529 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180418105129 $b ABA008
999    __
$a ok $b bmc $g 1288152 $s 1007479
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 32 $c 1 $d 121-133 $e 20170418 $i 1476-3524 $m Neurotoxicity research $n Neurotox Res $x MED00180457
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Nahrávání dat...

Možnosti archivace

Nahrávání dat...